SG3 Management’s Sarepta Therapeutics SRPT Stock Holding History

SG3 Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$781K	–	797
2022 Q1	$781K	Buy	10,000 +6,500	+186%	+$498K	0.02%	513
2021 Q4	$315K	Sell	3,500 -5,500	-61%	-$470K	0.01%	738
2021 Q3	$832K	Buy	+9,000	New	+$693K	0.03%	495
2021 Q2	–	Sell	-14,000	Closed	-$1.06M	–	1317
2021 Q1	$1.04M	Buy	14,000 +11,000	+367%	+$1.02M	0.03%	597
2020 Q4	$511K	Sell	3,000 -1,000	-25%	-$148K	0.01%	726
2020 Q3	$562K	Buy	4,000 +2,500	+167%	+$380K	0.02%	537
2020 Q2	$241K	Buy	+1,500	New	+$204K	0.02%	465
2019 Q1	–	Sell	-5,000	Closed	-$546K	–	386
2018 Q4	$546K	Buy	+5,000	New	+$625K	0.14%	111
2017 Q4	–	Sell	-3,500	Closed	-$159K	–	193
2017 Q3	$159K	Buy	+3,500	New	+$140K	0.04%	137

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

SG3 Management's SRPT Position: Q2 2022 in Review

SG3 Management sold out of Sarepta Therapeutics (SRPT) in Q2 2022, closing a stake of 10,000 shares — an estimated $781K sold.

SG3 Management first reported a position in SRPT in Q3 2017 and held it in 9 quarters. The position peaked at $1.04M in Q1 2021. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

SG3 Management reported no remaining Sarepta Therapeutics position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 10,000 Sarepta Therapeutics shares in Q2 2022, an estimated $781K.
SG3 Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 9 quarters.
SG3 Management's Sarepta Therapeutics position peaked at $1.04M in Q1 2021.
331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.